4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition

Abstract

FMS-like tyrosine kinase 3 (FLT3) mutation is strongly associated with poor prognosis in acute myeloid leukemia (AML). Though many FLT3 inhibitors have been developed for clinical application with 34%–56% complete remission rate, patients would develop resistance sooner or later after initial response to tyrosine kinase inhibitors (TKIs), such as gilteritinib. And increasing studies have shown that several resistance related mutations of FLT3 emerged during the AML progression. Thus, further investigation is warranted for these FLT3^mut AML patients to achieve a better treatment outcome. 4-Hydroxyphenyl retinamide (4-HPR) has been investigated extensively in animal models and clinical trials as an anticancer/chemopreventive agent and is currently used for protection against cancer development/recurrence, with minimal side effects. In this study, we performed gene-set enrichment analysis and found that down-regulated genes induced by 4-HPR were associated with FLT3-ITD gene sets. CD34⁺ AML stem/progenitor cells separated from 32 AML samples were treated with 4-HPR. Correlation analysis showed that AML cells with FLT3-ITD genetic alteration were more sensitive to 4-HPR treatment than those without FLT3-ITD. Next, we treated 22 primary AML cells with 4-HPR and found that 4-HPR was more toxic to AML cells with FLT3-ITD. These results indicated that 4-HPR was preferentially cytotoxic to all FLT3-ITD AML⁺ cells irrespective of stem/progenitor cells or blast cells. 4-HPR-induced reactive oxygen species (ROS) production and NF-κB inhibition might be the reason of 4-HPR selectivity on FLT3 mutated AML cells.

Keywords

4-Hydroxyphenyl retinamide / acute myeloid leukemia / FLT3 mutations / ROS induction / NF-κB inhibition

References

[1] ShortNJ, RyttingME, CortesJE. Acute myeloid leukaemia. Lancet, 2018, 392(10147): 593-606

[2] OthusM, KantarjianH, PetersdorfS, et al.. Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson. Leukemia, 2014, 28(2): 289-292

[3] ValkPJ, VerhaakRG, BeijenMA, et al.. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med, 2004, 350(16): 1617-1628

[4] SantosFP, JonesD, QiaoW, et al.. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer, 2011, 117(10): 2145-2155

[5] SchlenkRF, DohnerK, KrauterJ, et al.. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med, 2008, 358(18): 1909-1918

[6] SchnittgerS, SchochC, DugasM, et al.. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood, 2002, 100(1): 59-66

[7] ShenY, ZhuYM, FanX, et al.. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood, 2011, 118(20): 5593-5603

[8] KaziJU, RonnstrandL. FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. Physiol Rev, 2019, 99(3): 1433-1466

[9] ShortNJ, KonoplevaM, KadiaTM, et al.. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov, 2020, 10(4): 506-525

[10] SmithCC, LevisMJ, PerlAE, et al.. Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood, 2019, 134(Supplement_1): 14

[11] MaloneW, PerloffM, CrowellJ, et al.. Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs, 2003, 12(11): 1829-1842

[12] GaraventaA, LukschR, LoP M, et al.. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res, 2003, 9(6): 2032-2039

[13] Children’sO G, VillablancaJG, KrailoMD, et al.. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children’s Oncology Group (CCG 09709). J Clin Oncol, 2006, 24(21): 3423-3430

[14] PuduvalliVK, YungWK, HessKR, et al.. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol, 2004, 22(21): 4282-4289

[15] SchneiderBJ, WordenFP, GadgeelSM, et al.. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer. Invest New Drugs, 2009, 27(6): 571-578

[16] BushueN, WanYJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev, 2010, 62(13): 1285-1298

[17] GonzalezG J, Meza-EspinozaJP. Use of the International System for Human Cytogenetic Nomenclature (ISCN). Blood, 2006, 108(12): 3952-3953

[18] MoothaVK, LindgrenCM, ErikssonKF, et al.. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet, 2003, 34(3): 267-273

[19] SubramanianA, TamayoP, MoothaVK, et al.. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA, 2005, 102(43): 15545-15550

[20] MeyerSC, LevineRL. Translational implications of somatic genomics in acute myeloid leukaemia. The Lancet Oncology, 2014, 15(9): e382-e394

[21] CortesJ, PerlAE, DohnerH, et al.. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol, 2018, 19(7): 889-903

[22] CortesJE, KhaledS, MartinelliG, et al.. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2019, 20(7): 984-997

[23] GorceaCM, BurthemJ, TholouliE. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Future Oncol, 2018, 14(20): 1995-2004

[24] PerlAE, MartinelliG, CortesJE, et al.. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med, 2019, 381(18): 1728-1740

[25] ZhangH, MiJQ, FangH, et al.. Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci U S A, 2013, 110(14): 5606-5611

[26] WuJM, DiPietrantonioAM, HsiehTC. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis, 2001, 6(5): 377-388

[27] CooperJP, ReynoldsCP, ChoH, et al.. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. Exp Biol Med (Maywood), 2017, 242: 1178-1184

[28] OrientiI, FrancescangeliF, De AngelisML, et al.. A new bioavailable fenretinide formulation with antiproliferative, antimetabolic, and cytotoxic effects on solid tumors. Cell Death Dis, 2019, 10(7): 529

[29] OrientiI, SalvatiV, SetteG, et al.. A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells. J Exp Clin Cancer Res, 2019, 38(1): 373 Received Jul. 10, 2020; accepted Sep. 6, 2020)